314 related articles for article (PubMed ID: 33031714)
1. Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review.
Wheless JW
Expert Rev Neurother; 2020 Nov; 20(11):1085-1098. PubMed ID: 33031714
[TBL] [Abstract][Full Text] [Related]
2. Cenobamate tablets as a treatment for focal-onset seizures in adults.
Steinhoff BJ
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):161-172. PubMed ID: 33470139
[No Abstract] [Full Text] [Related]
3. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.
Carreño M; Gil-Nagel A; Serratosa JM; Toledo M; Rodriguez-Uranga JJ; Villanueva V
Epilepsia Open; 2024 Jun; 9(3):1051-1058. PubMed ID: 38573131
[TBL] [Abstract][Full Text] [Related]
4. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.
Sperling MR; Klein P; Aboumatar S; Gelfand M; Halford JJ; Krauss GL; Rosenfeld WE; Vossler DG; Wechsler R; Borchert L; Kamin M
Epilepsia; 2020 Jun; 61(6):1099-1108. PubMed ID: 32396252
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.
Lattanzi S; Trinka E; Zaccara G; Striano P; Del Giovane C; Silvestrini M; Brigo F
CNS Drugs; 2020 Nov; 34(11):1105-1120. PubMed ID: 32851590
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
Rosenfeld WE; Nisman A; Ferrari L
Epilepsy Res; 2021 May; 172():106592. PubMed ID: 33662894
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis.
Zhang L; Wang J; Wang C
Acta Neurol Scand; 2021 Jul; 144(1):58-66. PubMed ID: 33788253
[TBL] [Abstract][Full Text] [Related]
8. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study.
Serrano-Castro PJ; Ramírez-García T; Cabezudo-Garcia P; Garcia-Martin G; De La Parra J
CNS Drugs; 2024 Feb; 38(2):141-151. PubMed ID: 38265735
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study.
O'Dwyer R; Stern S; Wade CT; Guggilam A; Rosenfeld WE
Drugs Aging; 2024 Mar; 41(3):251-260. PubMed ID: 38446341
[TBL] [Abstract][Full Text] [Related]
10. Cenobamate: A New Adjunctive Agent for Drug-Resistant Focal Onset Epilepsy.
Buckley CT; Waters OR; DeMaagd G
Ann Pharmacother; 2021 Mar; 55(3):318-329. PubMed ID: 32623899
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability.
Roberti R; De Caro C; Iannone LF; Zaccara G; Lattanzi S; Russo E
CNS Drugs; 2021 Jun; 35(6):609-618. PubMed ID: 33993416
[TBL] [Abstract][Full Text] [Related]
12. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications.
Rosenfeld WE; Abou-Khalil B; Aboumatar S; Bhatia P; Biton V; Krauss GL; Sperling MR; Vossler DG; Klein P; Wechsler R
Epilepsia; 2021 Dec; 62(12):3016-3028. PubMed ID: 34633074
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL; Klein P; Brandt C; Lee SK; Milanov I; Milovanovic M; Steinhoff BJ; Kamin M
Lancet Neurol; 2020 Jan; 19(1):38-48. PubMed ID: 31734103
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study.
Varughese RT; Shah YD; Karkare S; Kothare SV
Epilepsy Behav; 2022 May; 130():108679. PubMed ID: 35381496
[TBL] [Abstract][Full Text] [Related]
15. Cenobamate for the treatment of focal epilepsies.
Strzelczyk A; Mann C; Willems LM; Rosenow F; Bauer S
Expert Opin Pharmacother; 2020 Dec; 21(18):2215-2223. PubMed ID: 32812825
[TBL] [Abstract][Full Text] [Related]
16. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: A systematic review and network meta-analysis.
Mulheron S; Leahy TP; McStravick M; Doran R; Delanty N
Seizure; 2024 May; 118():80-90. PubMed ID: 38643679
[TBL] [Abstract][Full Text] [Related]
17. Onset of efficacy and adverse events during Cenobamate titration period.
Steinhoff BJ; Ben-Menachem E; Brandt C; García Morales I; Rosenfeld WE; Santamarina E; Serratosa JM
Acta Neurol Scand; 2022 Sep; 146(3):265-275. PubMed ID: 35711112
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications.
Brandt C; Sánchez-Álvarez JC; Steinhoff BJ; Milanov I; Serratosa JM
Seizure; 2022 Mar; 96():86-93. PubMed ID: 35168142
[TBL] [Abstract][Full Text] [Related]
19. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: Post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study.
Aboumatar S; Ferrari L; Stern S; Wade CT; Weingarten M; Connor GS; Rosenfeld WE
Epilepsy Res; 2024 Feb; 200():107306. PubMed ID: 38340681
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects.
Vernillet L; Greene SA; Kamin M
Clin Pharmacol Drug Dev; 2020 May; 9(4):428-443. PubMed ID: 32087001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
